Great Valley Advisor Group, Inc. Summit Therapeutics Inc. Transaction History
Great Valley Advisor Group, Inc.
- $4.13 Billion
- Q1 2025
A detailed history of Great Valley Advisor Group, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 25,133 shares of SMMT stock, worth $720,311. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,133
Previous 25,101
0.13%
Holding current value
$720,311
Previous $448,000
8.04%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
246Shares Held
87.3MCall Options Held
1.77MPut Options Held
2.49M-
Baker Bros. Advisors LP New York, NY24.4MShares$700 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$334 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$226 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$188 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$139 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.77B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...